Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Telesis Bio Inc. (TBIO) generates news centered on automated DNA and mRNA synthesis technologies, strategic collaborations and corporate developments. The company describes itself as a public company based in San Diego, California, focused on enabling scientists to produce high-fidelity DNA and mRNA directly in their own laboratories using its Gibson SOLA Enzymatic Synthesis platform and BioXp benchtop systems.
News coverage for Telesis Bio often highlights progress and adoption of the Gibson SOLA™ platform, which the company presents as a non-toxic, high-fidelity and scalable enzymatic DNA and mRNA synthesis technology. Announcements have included licensing agreements, such as the deployment of Gibson SOLA at Regeneron Pharmaceuticals’ R&D core facilities, and collaborations that integrate Gibson SOLA with third-party automation platforms to support on-premises biofoundry capabilities.
Investors and researchers following TBIO can expect updates on partnerships and collaborations, including the company’s strategic research collaboration and license agreement with Pfizer related to enzymatic DNA synthesis for potential mRNA-based vaccines and other biopharma products. Additional news may cover agreements with automation and life sciences companies to co-develop and market integrated solutions for high-throughput nucleic acid synthesis.
Corporate and capital markets developments also appear in Telesis Bio’s news flow. Examples include restructuring activities, strategic focus on Gibson SOLA and BioXp mRNA solutions, reverse stock split actions, and the company’s decision to voluntarily delist from The Nasdaq Global Select Market and pursue quotation on over-the-counter markets. For anyone tracking TBIO, the news stream provides context on how the company is positioning its synthesis platforms, managing its cost structure and engaging with partners in synthetic biology and drug discovery workflows.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Telesis Bio Inc. (NASDAQ: TBIO) announced the expansion of its BioXp® Select Kit product line with two new kits for DNA amplification and scale-up. These kits enable automated and on-demand synthesis of transfection-scale DNA from customers' own DNA fragments or plasmid DNA. This innovation is expected to significantly reduce the time and steps required for DNA cloning and scaling, enhancing research workflows. Telesis Bio plans to release additional BioXp® kits throughout 2023, which will further improve processes like NGS Library Preparation and CRISPR gRNA synthesis.
Telesis Bio Inc. (NASDAQ: TBIO) reported a record revenue of $9.5 million for 4QFY22, reflecting a remarkable 208% increase compared to 4QFY21. The company's BioXp revenue rose 158% to $3.4 million. Gross margin improved to 68%, up from 29% year-over-year, despite operating expenses increasing to $14.3 million. The net loss narrowed to $8.1 million from $12.5 million the previous year. For 2023, Telesis Bio expects total revenue exceeding $45 million and gross margin between 55% and 59%. The company is focused on strategic investments to drive long-term growth and profitability.
Telesis Bio Inc. (NASDAQ: TBIO) announced that Daniel Gibson, Ph.D., CTO and Co-founder, will present at the Festival of Biologics on March 21, 2023. His talk, titled “Building Biology Overnight”, will focus on overcoming synthesis bottlenecks using hands-free automated synthetic biology solutions, particularly the award-winning BioXp® platform. Dr. Gibson will showcase the new SOLA technology, enhancing DNA synthesis by efficiently assembling complex synthetic genes and mRNA templates through a pre-manufactured library of short DNA oligos. This innovation aims to expedite timelines for applications in vaccine and therapeutics development.
FAQ
What is the current stock price of TRANSLATE BIO (TBIO)?
What is the market cap of TRANSLATE BIO (TBIO)?
